Study: NCT06336395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Oral/ intrathecal/intravenous/subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Oral/ intrathecal/intravenous/subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Oral/ intrathecal/intravenous/subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Asparaginase
Description: Intramuscular

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Asparaginase
Description: Intramuscular

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Asparaginase
Description: Intramuscular

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated asparaginase
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated asparaginase
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated asparaginase
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erwinase
Description: Optional for those allergic to E.coli/PEG L-asparaginase (intravenous)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erwinase
Description: Optional for those allergic to E.coli/PEG L-asparaginase (intravenous)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erwinase
Description: Optional for those allergic to E.coli/PEG L-asparaginase (intravenous)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Indicated only for ALL with BCR::ABL1 /BCR::ABL1-like/ tyrosine kinase fusion positive (oral)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Indicated only for ALL with BCR::ABL1 /BCR::ABL1-like/ tyrosine kinase fusion positive (oral)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Subcutaneous/ Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Subcutaneous/ Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Subcutaneous/ Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Intravenous